CoGenesis™ Cancer allows accurate molecular profiling of tumor tissues. With the use of next-generation sequencing, CoGenesis™ Cancer detects aberrations in cancer genes that are responsible for a wide range of cancers. Together with our actively growing pharmacogenomics database, CoGenesis™ Cancer provides valuable insights into the specific causes of each individual tumor, enabling clinicians to personalize treatment for cancer patients during routine oncology practice.
Different from hereditary cancer screening, CoGenesis™ Cancer panel provides clinically actionable results for cancer patients
CoGenesis™ Cancer is available from our partner’s clinics. Please contact us for more information.
 Dung T.L.E. et. al, A pan-cancer biomarker is identified that can predict successful response to cancer immunotherapy in human patients. Science, 2017; 28 JUL 2017 pp 409-413
 Gao G. et al ., Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. Int. J. Cancer, 2012; 131: E822-E829
 Kalemkerian, G et. al., Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. Journal Of Oncology Practice, 2018; 14(5), 323-327
 The American Society of Breast Surgeon, Consensus Guideline on Genetic Testing for Hereditary Breast Cancer, 2018